Retatrutide Dosage: What Did Phase 1 and Phase 2 Use?

What does retatrutide dosage mean on this page?

In human studies, staff gave the unapproved drug retatrutide as a shot. This page shows you the tested amounts and how long retatrutide remained in blood. Studies used 0.5 mg through 12 mg, often beginning low and raising the amount. Staff watched each person for side effects.

At six days, about half remained. The slow exit helps explain why study staff gave weekly shots. It doesn't make any study amount safe for you to use alone. No approved bottle or tested guide exists for mixing and storage.

These retatrutide dosage facts describe research, not personal care. They aren't instructions for you. In a real study, trained staff supply each shot under set rules. A study amount can't tell what fits your health.

Which retatrutide dosage did each study use?

Published human studies used the amounts below. Staff chose them for watched groups, not for you to use at home. A slash in the paper means the drug amount rose in planned steps; it doesn't mean a fraction or several shots at once.

**The first safety test appeared in Lancet in 2022:** The paper writes the weekly amounts as 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg. The study lasted 12 weeks and followed 72 adults with type 2 diabetes ^[4]. The shorter slash set shows fewer planned increases. The long set, 3/6/9/12, shows the full rise in that group. Starting low gave staff time to watch for trouble.

Phase 2 weight study, published in 2023: The 338 adults had target amounts of 1, 4, 8, or 12 mg, or placebo, each week for 48 weeks ^[1]. The paper lists fixed target groups. It also says some people had a slow start, but it doesn't give every step between the starting amount and the target.

**Phase 2 diabetes study, published in Lancet in 2023:** Staff raised the weekly drug amount from 0.5 to 12 mg over 36 weeks. The group had 281 adults with type 2 diabetes ^[2].

These facts show how each study ran. They aren't directions, and no form of retatrutide has approval. Staff picked amounts for people they could watch closely. Your age, health, and medicines may change the harm.

Why did one retatrutide shot remain for about a week?

The half-life was about 6 days. Half-life tells you how long the amount in blood takes to fall by half. The earliest human test measured that span ^[4]. The result suited the weekly shots given by study staff.

Retatrutide is a chain of 39-amino-acid parts, the small pieces that form protein. A fatty side chain, meaning an added piece attached to the drug, helps it cling to albumin. This common blood protein slows the drug's exit, so retatrutide stays for days instead of hours.

Human study staff placed one shot below the skin each week. They didn't test a shot into a vein, a shot into muscle, or a pill. No published human work supports those other forms for you.

How the drug enters and moves: The shot enters the fat layer just below the skin. The drug then moves into your blood. Its grip on albumin lets it travel longer than the plain protein chain would.

What changed as amounts rose: The early test and Phase 2 found more weight loss and lower blood sugar at higher amounts. They also found more gut trouble and a larger rise in pulse ^[1][2][4]. Staff began low and raised the amount with care. That study method doesn't make self-use safe. A bad effect may take time to fade.

Why is there no safe guide on how to reconstitute retatrutide?

No published standard tells a person how to mix retatrutide. In human studies, the maker supplies a ready form of the drug. Drug-making rules govern how it is made and checked. Trained staff give the shots and watch for harm.

Bottles sold for research often contain freeze-dried powder, meaning the water was removed for storage. People asking how to reconstitute retatrutide usually mean adding liquid to those bottles. Three facts matter:

• No sound lab test proves the powder matches the label or is safe for you to put into your body.
• No published test shows how long retatrutide remains sound in such a bottle.
• FDA warning letters said sellers broke federal food and drug law ^[6].

This page gives no mixing steps or seller links. A real lab would first identify the drug and measure its amount. The lab would also check for germs and harmful waste made by germs. Sellers don't give you those safeguards. Mixing can't prove what your bottle holds.

Which retatrutide side effects appeared at study amounts?

The first human test and Phase 2 studies found side effects mainly in your gut. The Retatrutide effects page covers all reported harms. Here, you can see each risk beside the study amounts.

Stomach and bowel: Higher doses brought more constipation, vomiting, nausea, and diarrhea. Most trouble came early or soon after an increase. In the Phase 2 weight study, up to 45% had nausea at 12 mg. Gut trouble caused most of the 18% who stopped that dose to leave ^[1].

Heart rate: The highest doses raised resting pulse about 5–7 beats a minute in Phase 2. Pulse rose most near week 24. Glucagon, one hormone imitated by the drug, can speed your heart ^[1]. Doctors don't know what that rise means after years of use.

Skin near the needle spot: About 8% in Phase 2 had a short-lived skin change ^[1]. Most cases were mild. The change stayed close to the spot.

Very low blood sugar: No severe case occurred in either Phase 2 weight study or the Phase 2 diabetes study when people weren't also taking insulin or an older pill that releases more insulin ^[1][2]. Either added drug may push blood sugar dangerously low. Show your full drug list to your doctor.

Loss of muscle and other tissue: Phase 2 scans showed that fat and lean tissue both fell. Lean tissue means your body's non-fat parts, including muscle, organs, and water. A 2025 study measured such losses with retatrutide and related drugs ^[8]. Older age or existing weakness can make muscle loss matter more. Your doctor would need to know every medicine you take.

Why is there no real retatrutide cost yet?

No approved retatrutide product exists, so there is no true store price. Insurers have no set price to cover. Compounding does not make retatrutide available for routine prescription care. A figure you see today isn't the price of an approved medicine.

Research bottles appear at many prices, but this site doesn't list or link to sellers. Sellers of those bottles have received FDA warning letters. A label can't confirm the drug, its strength, or its purity. A low price doesn't reduce that risk.

If retatrutide gains approval, the maker will set a price and insurers will bargain over payment. That hasn't happened. No public price promise has been made, so your future cost is unknown. A real price can exist only after an approved product reaches care.